🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

1/2 Following the DANGER SHOCK trial demonstrating reduced mortality with Impella in cardiogenic shock, the independent DSMB of the RECOVER IV trial has strongly recommended the trial be discontinued because of lack of equipoise. Therefore, we are ceasing enrollment in the trial.

Congratulations to PI Dr. Miguel Alvarez Villela, Dr. Arber Kodra, Dr. Christina Brennan, MD, MBA, CCRC, Dr. Michael Kim, Dr. Varinder Singh and the research team at Lenox Hill Hospital on their recent #ALLAYHF randomization! #atrialshunt #HFpEF #heartfailure #structuralheart #interventionalcardiology

1/ Joshua Goldberg Miguel Alvarez Villela Tanya Sharma Srihari S. Naidu, MD PERT Consortium Robert Zhang MD

“There is no need to change the STEMI-NSTEMI paradigm. I never see false negatives.” We published the article “The no false negative paradox in STEMI-NSTEMI diagnosis” in Heart (BMJ), and I’ll explain this paradox with a story: José de Alencar sees a patient with angina. 🧵

Three dimensional depiction of electrocardiographic leads

We discussed this observation on #CardioTwitter: several noted that administering a heparin bolus the ER (100 units/Kg, not max 4,000), rather than waiting until the cath lab, improves TIMI flow by the time the patient reaches the cath lab. This is now supported by an RCT!

Our own University of Utah Health Team bringing heart surgery to Honduras with Craig Selzman and Miguel Alvarez Villela . A collaborative effort with Open Heart Honduras (linkedin.com/in/coraz%C3%B3…) and University of Utah . UofUSurgery U of U Cardiovascular Medicine UofUCVSL #heartsurgery

University of Utah Health Team reaching the finish line with 10 cardiac surgeries in one week . Including left atrial myxoma with PA pressure of 150 mmHg 😳 . Successful collaboration with the amazing team Instituto Nacional Cardiopulmonar el Torax 🏥

Thrilled to share our paper just published in Circ: Heart Failure! Our #INTERMACS analysis evaluates functional capacity, quality of life, and survival outcomes to determine whether “cold and dry” patients derive the same benefit from #LVAD therapy. 🔗Read more here: ahajournals.org/doi/10.1161/CI…

Heart Failure patients with "cold and dry" profile derive similar benefit from LVAD therapy as "cold and wet" patients Varrias Dimitrios Miguel Alvarez Villela Amrita Balgobind Majd Al Deen #AHAJournals ahajrnls.org/4hx7BBa

🧵1/ Can we tap into the lymphatic system to relieve congestion in heart failure (HF)? A new feasibility study explores thoracic duct (TD) drainage as a novel decongestive strategy in HF. Let’s dive in! Husam Salah Abubaker Khalifa Jan Biegus Piotr Ponikowski doi.org/10.1007/s12265…

🆕📚Interventional #HeartFailure is revolutionizing #HF treatment w pharmacological & device-based therapies. Explore the history & unmet needs w a deep dive into training competencies & challenges. "Charting the Course for Careers in #Interventional HF: Training, Challenges, &

#Interventional_Heart_Failure 1⃣What it is 2⃣How you train for it 3⃣Where it is heading Charting the Course for Careers in Interventional Heart Failure: Training, Challenges, and Future Directions sciencedirect.com/science/articl… MyJSCAI Richard Cheng Miguel Alvarez Villela Navin Kapur

There’s a growing number of novel device therapies in heart failure but who’s the right patient for each one? Here we provide a framework to guide pt selection with real world examples of its use Marat Fudim, MD MHS Amrita Balgobind frontiersin.org/journals/cardi…

Medical therapy and outcomes in #REVIVED-#BCIS2 and #STICHES In this pooled individual participant data analysis of 1912 patients with ischaemic LV dysfunction, patients receiving medical therapy in REVIVED-BCIS2 had better outcomes than those enrolled in STICHES, regardless of